Reduction in the incidence of methicillin-resistant Staphylococcus aureus and ceftazidime-resistant Klebsiella pneumoniae following changes in a hospital antibiotic formulary

Clinical Infectious Diseases

Volumn 28, Issue 5, 1999, Pages 1062-1066

  Landman, David ^a   Chockalingam, Mira ^a   Quale, John M ^a,b  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIKACIN; AMPICILLIN; ANTIBIOTIC AGENT; BETA LACTAM ANTIBIOTIC; BETA LACTAMASE INHIBITOR; CEFAZOLIN; CEFOTAXIME; CEFOXITIN; CEFTAZIDIME; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; CLINDAMYCIN; GENTAMICIN; IMIPENEM; METICILLIN; METRONIDAZOLE; NAFCILLIN; PENICILLIN DERIVATIVE; PIPERACILLIN; PIPERACILLIN PLUS TAZOBACTAM; SULTAMICILLIN; VANCOMYCIN;

ACINETOBACTER; ARTICLE; BACTERIUM CULTURE; DRUG USE; HOSPITAL INFECTION; INCIDENCE; KLEBSIELLA PNEUMONIAE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NONHUMAN; PRIORITY JOURNAL; PUBLICATION;

EID: 0032907424     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/514743     Document Type: Article

References (32)

1. 1. Morris JG Jr, Shay DK, Hebden JN, et al. Enterococci resistant to multiple antimicrobial agents, including vancomycin: establishment of endemicity in a university medical center. Ann Intern Med 1995; 123:250-9.
2. 2. Quale J, Landman D, Atwood E, et al. Experience with a hospital-wide outbreak of vancomycin-resistant enterococci. Am J Infect Control 1996; 24:372-9.
3. 3. Wells CL, Juni BA, Cameron SB, et al. Stool carriage, clinical isolation, and mortality during an outbreak of vancomycin-resistant enterococci in hospitalized medical and/or surgical patients. Clin Infect Dis 1995; 21:45-50.
4. 4. Burven DR, Banerjee SN, Gaynes RP. Ceftazidime resistance among selected nosocomial gram-negative bacilli in the United States. J Infect Dis 1994; 170:1622-5.
5. 5. Naumovski L, Quinn JP, Miyashiro D, et al. Outbreak of ceftazidime resistance due to a novel extended-spectrum beta-lactamase in isolates from cancer patients. Antimicrob Agents Chemother 1992; 36:1991-6.
6. 6. Brun-Buisson C, Legrand P, Philippon A, Montravers F, Ansquer M, Duval J. Transferable enzymatic resistance to third-generation cephalosporins during nosocomial outbreak of multiresistant Klebsiella pneumoniae. Lancet 1987; 2:302-6.
7. 7. Meyer KS, Urban C, Eagan JA, Berger BJ, Rahal JJ. Nosocomial outbreak of Klebsiella infection resistant to late-generation cephalosporins. Ann Intern Med 1993; 119:353-8.
8. 8. Cohen SH, Morita MM, Bradford M. A seven-year experience with methicillin-resistant Staphylococcus aureus. Am J Med 1991; 91(suppl 3B): 233-7.
9. 9. Linnemann Jr CC, Moore P, Staneck JL, Pfaller MA. Reemergence of epidemic methicillin-resistant Staphylococcus aureus in a general hospital associated with changing staphylococcal strains. Am J Med 1991; 91(suppl 3B):238-44.
10. 10. Layton MC, Hierholzer WJ Jr, Patterson JE. The evolving epidemiology of methicillin-resistant Staphylococcus aureus at a university hospital. Infect Control Hosp Epidemiol 1995; 16:12-7.
11. 11. Anonymous. Guidelines for the control of epidemic methicillin-resistant Staphylococcus aureus: report of a combined working party of the Hospital Infection Society for Antimicrobial Chemotherapy. J Hosp Infect 1986; 7:193-201.
12. 12. Centers for Disease Control and Prevention. Recommendations for preventing the spread of vancomycin resistance. Recommendations of the Hospital Infection Control Practices Advisory Committee (HICPAC). MMWR Morb Mortal Wkly Rep 1995; 44(RR-12):1-13.
13. 13. Pear SM, Williamson TH, Bettin KM, Gerding DN, Galgiani JN. Decrease in nosocomial Clostridium difficile-associated diarrhea by restricting clindamycin use. Ann Intern Med 1994; 120:272-7.
14. 14. Nelson DE, Auerbach SB, Baltch AL, et al. Epidemic Clostridium difficile associated diarrhea: role of second- and third-generation cephalosporins. Infect Control Hosp Epidemiol 1994; 15:88-94.
15. 15. Quale J, Landman D, Saurina G, Atwood E, Ditore V, Patel K. Manipulation of a hospital antimicrobial formulary to control an outbreak of vancomycin-resistant enterococci. Clin Infect Dis 1996; 23:1020-5.
16. 16. National Committee for Clinical Laboratory Standards. Performance standards for antimicrobial disk susceptibility tests: approved standard. NCCLS document M2-A5. Villanova, Pennsylvania: National Committee for Clinical Laboratory Standards, 1993.
17. 17. Schaberg DR, Culver DH, Gaynes RP. Major trends in the microbial etiology of nosocomial infection. Am J Med 1991; 91(suppl 3B):72 5.
18. 18. Gold HS, Moellering RC Jr. Antimicrobial-drug resistance. N Engl J Med 1996; 335:1445-53.
19. 19. Wenzel RP, Nettleman MD, Jones RN, Pfaller MA, Methicillin-resistant Staphylococcus aureus: implications for the 1990s and effective control measures. Am J Med 1991; 91(suppl 3B):221-7.
20. 20. Cantoni L, Wenger A, Glauser MP, Bille J. Comparative efficacy of amoxicillin-clavulanate, cloxacillin, and vancomycin against methicillin-sensitive and methicillin-resistant Staphylococcus aureus endocarditis in rats. J Infect Dis 1989; 159:989-93.
21. 21. Franciolli M, Bille J, Glauser MP, Morcillon P. Beta-lactam resistance mechanisms of methicillin-resistant Staphylococcus aureus. J Infect Dis 1991; 163:514-23.
22. 22. Hirano L, Bayer AS. Beta-lactam-beta-lactamase-inhibitor combinations are active in experimental endocarditis caused by beta-lactamase-producing oxacillin-resistant staphylococci. Antimicrob Agents Chemother 1991; 15:685-90.
23. 23. Chambers HF, Kartalija M, Sande M. Ampicillin, sulbactam, and rifampin combination treatment of experimental methicillin-resistant Staphylococcus aureus endocarditis in rabbits. J Infect Dis 1995; 171:897-902.
24. 24. Bauemfeind A, Chong Y, Schweighart S. Extended broad spectrum betalactamase in Klebsiella pneumoniae including resistance to cephamycins. Infection 1989; 17:316-21.
25. 25. Moosdeen F. The evolution of resistance to cephalosporins. Clin Infect Dis 1997, 24:487-93.
26. 26. Jacoby GA, Carreras I. Activities of beta-lactam antibiotics against Escherichia coli strains producing extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1990; 34:858-62.
27. 27. Rice LB, Carias LL, Shlaes DM. In vivo efficacies of beta-lactam-beta-lactamase inhibitor combinations against a TEM-26-producing strain of Klebsiella pneumoniae. Antimicrob Agents Chemother 1994; 38:2663-4.
28. 28. Leleu G, Kitzis MD, Vallois JM, Gutmann L, Decazes JM. Different ratios of the piperacillin-tazobactam combination for treatment of experimental meningitis due to Klebsiella pneumoniae producing the TEM-3 extended-spectrum beta-lactamase. Antimicrob Agents Chemother 1994; 38:195-9.
29. 29. Mentec H, Vallois JM, Bure A, Saleh-Mghir A, Jehl F, Carbon C. Piperacillin, tazobactam, and gentamicin alone or combined in an endocarditis model of infection by a TEM-3-producing strain of Klebsiella pneumoniae or its susceptible variant. Antimicrob Agents Chemother 1992; 36: 1883-9.
30. 30. Caron F, Gutmann L, Bure A, et al. Ceftriaxone-sulbactam combination in rabbit endocarditis caused by a strain of Klebsiella pneumoniae producing extended-broad spectrum TEM-3 beta lactamase. Antimicrob Agents Chemother 1990; 34:2070-4.
31. 31. Jacoby GA, Medeiros AA. More extended-spectrum beta-lactamases. Antimicrob Agents Chemother 1991; 35:1697-704.
32. 32. Pena C, Pujol M, Ardanuy C, et al. Epidemiology and successful control of a large outbreak due to Klebsiella pneumoniae producing extended-spectrum β-lactamases. Amtimicrob Agents Chemother 1998; 42:53-8.